Tenofovir May Protect Against Herpes Simplex
Tenofovir May Protect Against Herpes Simplex
Pablo Barreiro
Department of Infectious Diseases, Hospital Carlos III-La Paz University Hospital. Madrid, Spain
*Correspondence: Pablo Barreiro, Email not available
Abstract
The major message of the CAPRISA-004 trial (Abdool-Karim, et al. Science. 2010;329:1168-74), originally reported in July 2010, was that a vaginal microbicide gel containing 1% tenofovir could reduce the risk of HIV infection among promiscuous women by 39%.
